查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1190712

电子医学/生物电子医学市场 - 增长、趋势、COVID-19 影响和预测 (2023-2028)

Electroceuticals/Bioelectric Medicine Market- Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 116 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

电子医疗/生物电子医疗市场预计在预测期内 (2022-2027) 以 7.8% 的复合年增长率增长。

COVID-19 疫情对市场产生了重大影响。 高感染率和缺乏治疗继续困扰着许多国家，并使它们的经济和卫生系统不堪重负。 在 COVID-19 流行期间，择期手术已无限期推迟，以确保有能力处理急诊病例并避免择期手术患者暴露于 COVID-19。 此外，根据 2021 年 8 月发表的文章“COVID-19 大流行对希腊西北部心臟电子设备植入的影响”，冠状病毒病 (COVID-19) 大流行影响了与心血管相关的医院就诊，并产生重大影响关于住院。 从头移植和替代在第一个锁定期间显着下降，但在第二个锁定期间没有显着变化。

在全球范围内，慢性病患病率上升是推动市场发展的主要因素。 例如，根据世界卫生组织 (WHO) 2021 年 4 月的报告，非传染性疾病 (NCDs)，也称为慢性病，是影响遗传、生理、环境和行为因素的长期疾病。它被认为是多种因素综合作用的结果。 根据2021年7月发表的《印度人非传染性疾病患病率为每千人116人：报告》一文，印度非传染性疾病患病率为每千人11人，其中高血压、胃肠道疾病和糖尿病居首位负担。 此外，预计在预测期内，有神经和 CVD 疾病风险的老年人口增加将推动市场增长。

生物电子医学用于治疗多种疾病和病症，包括癌症、类风湿性关节炎、炎症性肠病、肥胖症、糖尿病、哮喘、瘫痪、失明、出血、缺血、器官移植、心脏病和神经退行性疾□□病。有望为疾病的诊断和治疗带来新的认识 基于过去十年的快速发展，该领域正在迅速扩大。 技术创新正在使设备变得更小、侵入性更小，并且在未来几年内，公司将为市场带来新的应用，例如周围神经病变、关节炎、慢性阻塞性肺病、心力衰竭和 1 型糖尿病正在出现。

市场进入者也在开发生物电子医学。 例如，GE Research 生物医学团队正在展示一种新型非侵入性方法，该方法使用超声波来调节身体代谢和炎症控制系统的功能障碍。 生物电子医学的研究传统上依赖于植入式设备来刺激神经以达到治疗效果。 GE 的一个研究团队展示了使用无创超声技术对目标器官内的神经功能进行直接和精确的刺激。 GE研究团队的初步研究结果表明，需要对超声用于周围神经调节进行更多的投资和研究，需要超声设备工程师和神经科学家之间的合作。表明有 因此，它显示了生物医药市场的潜力和投资需求。

研究人员目前专注于开发各种基于生物电子学的治疗设备，用于肿瘤刺激和神经调节。 这允许调节癌症信号通路，恢復健康的电脉冲模式，并预防癌症进展。 生物电医学的最新进展可能被证明是一种比化疗和手术更自然、更安全的癌症治疗方法，后者有许多副作用。 目前，除了化疗之外，电场疗法还用于某些类型癌症的患者，以提高生存率和安全性。 例如，Bryne 等人表明，使用称为“离子电渗疗法”的低直流电场，可以迫使高浓度的局部药物深入肿瘤。

另外，根据2020年12月发表的论文“Core Concept”，“生物电医学的兴起将引起研究人员、患者和产业界的兴趣”，製药行业也热情高涨。 强生公司的产品组合目前包括多种生物电子设备。 这可能会在预测期内推动市场增长。

因此，上述因素预计将在预测期内推动市场增长。

主要市场趋势

在电子医学/生物电子医学市场，心律失常领域有望占据主要市场份额

预计在预测期内，心律失常部分将占市场增长的主要市场份额。 根据 2021 年 2 月发表的题为“房颤全球流行病学”的文章，心律失常患病率上升是市场增长的主要驱动力。 日益严重的流行病和公共卫生挑战”心房颤动是最常见的心律失常。 在全球范围内，估计到 2050 年，美国将有 6-12 百万人，到 2060 年欧洲将有 1790 万人患有这种疾病。 心房颤动是缺血性中风的主要危险因素，并造成显着的发病率和死亡率的显着经济负担。 此外，根据美国国家慢性病预防中心 (CDC) 健康促进、心脏病和中风预防部 2021 年 9 月更新的事实，到 2030 年美国将有 1210 万人患有心房颤动 (AFib)。估计的。 在美国，据说每年有超过 454,000 例以房颤为主要疾病的住院治疗发生。

此外，除颤器和心臟起搏器等产品的广泛接受也在推动市场增长。 此外，技术进步和产品批准的增加也推动了该细分市场的增长。 例如，2020 年 7 月，雅培公司的 Gallant 系列植入式心律转復除颤器和采用蓝牙技术的心臟再同步治疗除颤器获得了美国食品和药物管理局的批准。 远程数据跟踪设备、安全磁共振成像 (MRI) 设备和数据记录功能等先进起搏器技术能力推动了该领域的增长。

预计北美将占据很大的市场份额，预计在预测期内也会如此。

COVID-19 在时间上与院外心臟骤停的增加有关。 根据 2021 年 5 月发表的文章“COVID-19 爆发期间的植入式心臟復律除颤器电击”，纽约市、新奥尔良和波士顿在 COVID-19 高活动期间发生的除颤器电击事件有所增加。 COVID-19 影响心血管系统，可导致心肌梗塞、血管内血栓形成和心律失常。 装有植入式心律转復除颤器 (ICD) 的人因心律失常而发生心臟骤停的风险增加。 ICD 休克率峰值似乎也与 COVID-19 峰值暂时相关。 然而，美敦力公布的美国人口调查数据显示，在 COVID-19 流行期间，慢性疼痛患者的生活有些艰难，慢性背痛目前呈上升趋势。儘管 87% 的疼痛和腿痛患者表示他们的疼痛自两年前的 2020 年 3 月流行病开始以来没有改善或恶化，在 COVID-19 爆发期间没有提供任何护理。被发现经历了延迟 调查还显示，绝大多数人希望有更多的治疗选择，但对脊髓刺激和靶向给药选择的认识仍然相对较低。 这是一个机会，可以让患者了解减轻疼痛的所有可用选择。

日益老龄化的人口、慢性病的流行以及对先进和高质量医疗保健的需求正在给医疗保健带来巨大压力，以跟上不断增长的人口。 根据美国人口普查局的 2021 年老年人报告，目前美国有超过 5400 万 65 岁及以上的成年人，约占全国人口的 16.5%。 居住在美国的老年人口数量持续增长。 到 2050 年，65 岁及以上的成年人总数预计将增加到 8570 万，约占美国总人口的 20%。

癌症、心血管疾病、糖尿病等传染病和慢性病也在不断增加。 据世界癌症观察站（Globocan）2020年统计，2020年全球新增癌症患者人数为1930万男性和女性，预计到2040年，男性和女性新增癌症患者人数将达到3020万。 因此，这对于快速诊断和治疗疾病的生物电子医学市场来说是一个巨大的潜力。

此外，Biotronik 和 Medtronic 等历史悠久的市场参与者的存在也推动了该地区的市场增长。 此外，有利的政府支持和区域产品批准也在推动市场增长。 例如，专注于治疗慢性自身免疫性疾病患者的私人控股临床阶段生物电子医疗公司 Setpoint Medical 对多种生物製剂表现出不完全反应或不耐受。该公司已获得美国药物管理局的突破性设备指定用于类风湿性关节炎患者的新型生物电子设备。

竞争格局

电子医学/生物电子医学市场分散且竞争激烈，由几家大型企业组成。 市场上的公司包括 SetPoint Medical、Sky Medical Technology、Cala Health、Boston Scientific Corporation、Abbott、Medtronic、Biotronik SE &Co.KG、Cochlear Ltd.、Sonova、LivaNova PLC、ElectroCore Inc、NeuroPace, Inc、Koninklijke Philips N.V.、NEVRO CORP., WEINMANN Emergency Medical Technology GmbH+Co.KG.

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第1章介绍

  • 研究假设和市场定义
  • 调查范围

第2章研究方法论

第 3 章执行摘要

第4章市场动态

  • 市场概览
  • 市场驱动因素
    • 老年人口增加以及相关的神经和心血管疾病患病率增加
    • 技术进步
  • 市场製约因素
    • 电子医疗设备成本高
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：100 万美元）

  • 按设备类型
    • 植入式电疗设备
    • 无创电疗仪
  • 按产品分类
    • 除颤器
    • 起搏器
    • 刺激器
    • 其他
  • 通过申请
    • 心律失常
    • 疼痛管理
    • 帕金森病
    • 抑郁症
    • 其他
  • 最终用户
    • 医院
    • 诊所
    • 其他
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东和非洲
      • 海湾合作委员会
      • 南非
      • 其他中东和非洲地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章竞争格局

  • 公司简介
    • SetPoint Medical
    • Sky Medical Technology
    • Cala Health
    • Boston Scientific Corporation
    • Abbott Laboratories
    • Medtronic
    • Biotronik SE & Co. KG
    • Cochlear Ltd.
    • Sonova
    • LivaNova PLC.
    • ElectroCore Inc.
    • NeuroPace, Inc.
    • Koninklijke Philips N.V.
    • NEVRO CORP.
    • WEINMANN Emergency Medical Technology GmbH+Co. KG

第7章 市场机会与今后动向

简介目录
Product Code: 91075

The electroceuticals/bioelectric medicine market is projected to register a CAGR of 7.8% during the forecast period (2022-2027).

The COVID-19 epidemic has had a significant impact on the market. Due to the high rate of infection and the lack of treatment, many countries were suffering and continue to burden their economies and health care systems. Elective procedures have been postponed indefinitely during the COVID-19 pandemic to provide capacity to deal with the emergency caseload and avoid exposing elective patients to COVID-19. Also, as per the article published in August 2021 titled "Impact of COVID-19 pandemic on cardiac electronic device implantations in Northwestern Greece", The coronavirus disease (COVID-19) pandemic seems to have a significant impact on cardiovascular-related hospital visits and admissions. During the first lockdown period, both de novo implantations and replacements decreased significantly, while there was no significant change during the second lockdown period.

Globally, the rising prevalence of chronic disorders is a major factor driving the market forward. For instance, as per the April 2021 report of the World Health Organization (WHO), non-communicable diseases (NCDs), also known as chronic diseases, are long-duration diseases and are the result of a combination of genetic, physiological, environmental, and behavioral factor. According to the article titled ' Prevalence of Non-Communicable Diseases Among Indiands is 116 per 1,000 : Report' published in July 2021 Prevalence of non-communicable diseases in India is 11 per 1,000 population with hypertension, digestive diseases and diabetes leading the burden. Additionally, an increase in the geriatric population at risk of neurological and CVD diseases is expected to fuel market growth over the forecast period.

Bioelectronic Medicine promises to bring new insights into diagnosing and treating diseases and conditions as varied as cancer, rheumatoid arthritis, inflammatory bowel disease, obesity, diabetes, asthma, paralysis, blindness, bleeding, ischemia, and organ transplantation, cardiovascular disease, neurodegenerative diseases, and others. Building on a surge of progress in the past decade, the field is rapidly expanding. Technical innovations are making devices smaller and less invasive, with companies bringing new applications to market in the next several years, including for peripheral neuropathy, arthritis, chronic obstructive pulmonary disease, heart failure, and Type 1 diabetes.

Bioelectric Medicine is being developed by market participants as well. For example, GE Research's bioelectronic medicine team is using ultrasound to demonstrate potentially groundbreaking non-invasive methods to regulate dysfunction in the body's metabolic or inflammatory control systems. Bioelectronic medicine research traditionally relied on implanted devices to stimulate nerves and achieve therapeutic results. The GE Research team demonstrates the precise stimulation of nerve features directly within target organs using a non-invasive ultrasound technique. The preliminary findings of the GE Research team indicate that more investment and research into the use of ultrasound for peripheral neuromodulation is warranted and that increased collaboration between ultrasound device engineers and neuroscientists will be required. Hence, showing potential and simultaneously the need for investment in the biomedicine market.

Researchers are now looking into developing various bioelectronics-based therapeutic devices for tumor stimulation and neural modulation. This allows for the control of cancer signaling pathways, the restoration of healthy electrical impulse patterns, and the prevention of cancer progression. Recent advancements in bioelectric Medicine may prove to be a more natural and safe approach to cancer treatment than chemotherapy and surgery, both of which have numerous side effects. In today's world, patients with certain types of cancer are given electric field therapies in addition to chemotherapy to improve survival and safety. For instance, Bryne et al. showed that a high concentration of localized drugs could be forced deep inside the tumors using low direct current electric fields, referred to as "iontophoretic chemotherapy".

Also," per the article published in December 2020, "Core Concept: The rise of bioelectric medicine sparks interest among researchers, patients, and industry," the ph,"maceutical industry is also on board. Johnson & Johnson's portfolio now includes several bioelectronic devices. This is likely to boost the market growth over the forecast period.

Thus the above mentioned factors are expected to drive the growth of the market during the forecast period.

Key Market Trends

The Arrhythmia Segment is Expected to Hold a Major Market Share in the Electroceuticals/Bioelectric Medicine Market

The Arrhythmia segment is expected to hold a major market share in the growth of the market during the forecast period. The rising prevalence of arrhythmia is the major factor driving market growth as per the article published in February 2021 titled "Global Epidemiology of Atrial Fibrillation: An Increasing Epidemic and Public Health Challenge," Atrial fibrillation is the most frequent cardiac arrhythmia. It has been estimated that 6-12 million people worldwide will suffer from this condition in United States by 2050 and 17.9 million people in Europe by 2060. Atrial fibrillation is a major risk factor for ischemic stroke and provokes an important economic burden along with significant morbidity and mortality. Also, according to the National Center for Chronic Disease Prevention (CDC) and Health Promotion, Division for Heart Disease and Stroke Prevention facts updated on September 2021, it is estimated that 12.1 million people in United States will have Atrial fibrillation (AFib) in 2030. According to the same source, more than 454,000 hospitalizations with AFib as the primary diagnosis happen yearly in United States.

Furthermore, the products such as defibrillators and pacemakers are widely accepted by the population, which is also boosting the market growth. Additionally, growing technological advances and product approvals drive segment growth. For example, in July 2020, Abbott Laboratories received approval from United States Food and Drug Administration for its Gallant line, which includes an implanted cardioverter-defibrillator and a cardiac resynchronization therapy defibrillator with Bluetooth technology. Advance pacemaker technology features such as remote data tracking devices, secure magnetic resonance imaging (MRI) devices, and data recording functionality enhance segment growth.

North America is Expected to Hold a significant share in the market and is expected to do the Same in the Forecast Period.

COVID-19 was temporally associated with an increase in out-of-hospital cardiac arrests. As per the article published in May 2021 on "Implantable Cardioverter-Defibrillator Shocks During COVID-19 Outbreak", Defibrillator shock episodes increased during the higher COVID-19 activity in New York City, New Orleans, and Boston. COVID-19 can affect the cardiovascular system, resulting in myocardial injury, intravascular thrombosis and arrhythmias. Individuals with an implantable cardioverter-defibrillator (ICD) are at increased risk for arrhythmic sudden cardiac arrest. Spikes in ICD shock rates also appeared to be temporally associated with the COVID-19 surge. However, the data released from Medtronic's survey on United States population demonstrating several struggles for those with chronic pain during the COVID-19 pandemic found that 44% of current chronic back and leg pain sufferers experienced care delays during the COVID-19 pandemic despite 87% reporting that their pain has not improved - or has even worsened since the pandemic began two years ago in March 2020. The survey also demonstrated that an overwhelming majority want more treatment options, yet awareness of spinal cord stimulation and targeted drug delivery options remains relatively low. That represents an opportunity to educate patients about the full range of options available to help alleviate their pain.

The rising geriatric population, increasing prevalence of chronic diseases, and demand for advanced quality healthcare are putting immense pressure on healthcare to meet the population's increasing demand. As per United States Census Bureau's 2021 senior report, More than 54 million adults ages 65 and older live in United States today, accounting for about 16.5% of the nation's population. The number of older adults living in United States is growing. By 2050, the total number of adults ages 65 and older is projected to rise to 85.7 million, roughly 20% of the overall United States population.

There is an increasing prevalence of infectious and chronic diseases such as cancer, cardiovascular, diabetes, and many more. According to the Global Cancer Observatory (Globocan) Statistics 2020, there were 19.3 million new cases of cancer all over the world, accounting for both sexes in 2020, and the same source reported that the incidence of cancer was growing at a rapid pace in the world and estimated that the number of new cases of cancer in both sexes will reach to 30.2 million by 2040. Hence, this is huge potential for the bioelectric medicine market to quickly diagnose and treat diseases.

Furthermore, the presence of well-established market players such as Biotronik and Medtronic is also supporting the market growth in the region. Besides, favorable government support and regional product approvals also drive market growth. For instance, SetPoint Medical, a privately held clinical-stage bioelectronic medicine company dedicated to treating patients with chronic autoimmune diseases, has got a Breakthrough Device Designation from United States and Drug Administration for the use of its novel bioelectronic device for patients with rheumatoid arthritis who have an incomplete response to or are intolerant to multiple biologic drugs.

Competitive Landscape

The electroceuticals/bioelectric medicine market is fragmented and competitive and consists of several major players. Some of the players operating in the market are SetPoint Medical, Sky Medical Technology, Cala Health, Boston Scientific Corporation, Abbott, Medtronic, Biotronik SE & Co. KG, Cochlear Ltd., Sonova, LivaNova PLC., ElectroCore Inc., NeuroPace, Inc., Koninklijke Philips N.V., NEVRO CORP., and WEINMANN Emergency Medical Technology GmbH + Co. KG.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Geriatric Population and Subsequent Growth in the Prevalence of Neurological & Cardiovascular Disorders
    • 4.2.2 Technological Advancements
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Electroceutical Devices
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Device Type
    • 5.1.1 Implantable Electroceutical Devices
    • 5.1.2 Non-invasive Electroceutical Devices
  • 5.2 By Product
    • 5.2.1 Defibrillators
    • 5.2.2 Pacemakers
    • 5.2.3 Stimulators
    • 5.2.4 Others
  • 5.3 By Application
    • 5.3.1 Arrhythmia
    • 5.3.2 Pain Management
    • 5.3.3 Parkinson's Disease
    • 5.3.4 Depression
    • 5.3.5 Others
  • 5.4 End User
    • 5.4.1 Hospitals
    • 5.4.2 Clinics
    • 5.4.3 Others
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle-East and Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle-East and Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 SetPoint Medical
    • 6.1.2 Sky Medical Technology
    • 6.1.3 Cala Health
    • 6.1.4 Boston Scientific Corporation
    • 6.1.5 Abbott Laboratories
    • 6.1.6 Medtronic
    • 6.1.7 Biotronik SE & Co. KG
    • 6.1.8 Cochlear Ltd.
    • 6.1.9 Sonova
    • 6.1.10 LivaNova PLC.
    • 6.1.11 ElectroCore Inc.
    • 6.1.12 NeuroPace, Inc.
    • 6.1.13 Koninklijke Philips N.V.
    • 6.1.14 NEVRO CORP.
    • 6.1.15 WEINMANN Emergency Medical Technology GmbH + Co. KG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS